Introduction {#sec1-1}
============

There are approximately 25 million inpatient surgical procedures performed every year in the United States. A primary concern and challenge for patients and physicians is adequate periprocedural pain care. Despite advances in technology including continuous peripheral nerve catheters and ultrasound guided nerve blocks, \> 80% of patients report inadequate pain control resulting in persistent postoperative pain, extended hospital stay, and impaired rehabilitation.\[[@ref1]\] Overtreatment may result in adverse events associated with excessive analgesic usage including increased morbidity and mortality, a higher risk of cardiac, pulmonary, gastrointestinal, and immune complications, and a higher rate of thromboembolic events. Other side-effects include central nervous system (CNS) mediated sedation and pulmonary complications including aspiration and atelectasis.\[[@ref2]\]

Pharmacological Properties {#sec1-2}
==========================

Ketamine has been found to be an ideal anesthetic due to its dose-dependent nature of producing analgesia, amnesia, unconsciousness, and akinesia.\[[@ref2]\] The dosage is well-established single bolus and consistent across patients.\[[@ref3]\] It has been suggested in animals that in addition to low-grade analgesia and high dose anesthesia ketamine could work in synergy with opioids at a dose termed the third dose range of ketamine where ketamine would be devoid of analgesic effects.\[[@ref4]\] Clinical studies are required to confirm the third dose effect of ketamine in humans.

Ketamine is a noncompetitive antagonist at NMDA receptor with analgesic and anti-hyperalgesic properties. Its chiral center on the C~2~ atom of the ketamine cyclohexane ring gives rise to two enantiomers of ketamine (S(+)− and R(−)−).\[[@ref5][@ref6]\] It binds to the phencyclidinic site on postsynaptic channels and reduces the frequency and opening time of ion channels.\[[@ref7]\] This blockade by ketamine at the NMDA receptors is dose-dependent in that the rate of onset and the recovery from blockade are increased by applying NMDA agonists.\[[@ref8]\] The blockade at NMDA occurs by two different mechanisms. Firstly, by blocking the open channel, it subsequently reduces the mean open time of the channel. Secondly, upon binding to the closed receptor, it decreases the frequency of channel opening by an allosteric mechanism. Ketamine at lower concentrations predominantly causes blockade of the closed channel, whereas at higher concentrations it results in the blockade of both open and closed channels. These differences in the mechanism of receptor blockade based on ketamine concentrations have clinical implications. At low concentrations, analgesic properties are evident, whereas at higher concentrations anesthetic properties become apparent.\[[@ref8]\] It\'s noncompetitive nature allows glutamate to continue binding to these sites. In chronic pain states, upregulation of the NMDA receptor results in increased central sensitization and hyperalgesia. As a result, antagonists such as ketamine have been seen to stop afferent nociceptive transmission to the brain.\[[@ref6][@ref9]\] Ketamine also maintains blood pressure and preserves spontaneous breathing and laryngeal reflexes.\[[@ref10]\] The S(+) isomer increases anesthetic potency two-fold over the racemic mixture while decreasing the psychotomimetic side effects.\[[@ref11]\] The second enantiomer, S(−) ketamine, has been suggested to have anti-hyperalgesic properties.\[[@ref12]\]

Various *in vitro* studies have demonstrated that ketamine blocks the high-affinity state of the dopamine D2 receptor. This might explain the psychomimetic effects occurring during emergence, as well as explain the catalepsy seen during peak anesthetic effects.\[[@ref13]\] Other *in vitro* studies have also demonstrated that ketamine has anti-inflammatory effects as it reduces tumor necrosis factor alpha, interleukin-6 (IL-6) and IL-8 levels, and also suppresses NF-KB expression which has a supposedly pivotal role in pro-inflammatory response. However, the exact mechanism by which it exerts the anti-inflammatory effect remains unclear.\[[@ref14]\]

Routes and Doses for Ketamine {#sec1-3}
=============================

Ketamine can be given via different routes: oral (PO), subcutaneous (SC), continuous SC infusion, per rectum, intramuscular (IM), intravenous (IV) and transdermal. Intranasal solutions and powders have also been used. The most common route used postoperatively is the IV route.

Doses Vary Upon the Route Of administration {#sec1-4}
===========================================

The usual PO starting dose is 10-25 mg q8h, and intervals of q4-12 dosing have been reported. The dose can be increased up to 0.5-1 mg/kg q8h. Maximum reported dose is 200 mg q 6 h. For transdermal administration use 5-15% in Pluronic Lecithin Organogel; it is often combined with ketoprofen 10% and lidocaine 5%. [Table 1](#T1){ref-type="table"} contains some useful instructions for patients in need of ketamine therapy to ensure patient safety. The SC dose is 10-25 mg (0.2-0.5 mg/kg) administered intermittently as needed. For example, it is commonly used for wound dressing changes and wound debridements. Single analgesic doses of ketamine can range from 0.2 to 0.5 mg/kg IV and 0.5-1.0 mg/kg IM given over 1-2 min. Larger doses can cause respiratory depression.\[[@ref7]\] Continuous IV infusions are usually started at 0.1-0.2 mg/kg/h. Small doses of an antisialogogue may be necessary to prevent excessive salivation.\[[@ref15]\] At higher doses, dissociative states can be induced by disconnection of the thalamoneocortical and limbic systems.\[[@ref16]\]
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Patient education handout
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Ketamine for the Treatment of Chronic and Acute Pain {#sec1-5}
====================================================

Ketamine has been used for the treatment of chronic and acute pain. An evidence-based study on the use of ketamine in chronic pain was done by Correll *et al*.\[[@ref17]\] who conducted a retrospective review of 33 patients with the chronic regional pain syndrome (CRPS) on treatment with subanesthetic ketamine infusion therapy. The study demonstrated some evidence that low dose ketamine infusion may provide safe and effective treatment to selected patients with intolerable CRPS. The concerns in this study were hepatic dysfunction and CNS side effects.

A large retrospective study done on the efficacy and tolerability of ketamine for perioperative control of acute pain in adults was conducted by Bell *et al*.\[[@ref18]\] Assessment of 37 trials revealed that 27 of 37 trials reduced pain intensity or rescue pain medication requirement or both perioperatively. Quantitative analysis showed that ketamine in the first 24 h after surgery reduced morphine requirements and decreased the incidence of postoperative nausea and vomiting. The authors did state that since the review was heterogeneous, interpretation of the data should be done with caution especially while suggesting a regimen for the use of ketamine.

For example, as shown in [Table 2](#T2){ref-type="table"}, the following ketamine flow sheet is used by the pain service at a tertiary care academic institution. It is a conservative ketamine flow sheet with suggested ketamine infusion rates based on patient weight for starting a ketamine continuous infusion. The recommended ketamine dosage for initiation of therapy ranges from 60 to 120 µg/kg/h (0.06-0.12 mg/kg/h). It can be titrated to effect and increased appropriately with observation.
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Suggested ketamine infusion rates based on patient\'s weight
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Norketamine is produced after IV injection. While little research has been performed on the analgesic characteristics of norketamine, a recent human study conducted to evaluate the effects of norketamine on acute ketamine analgesia suggests no correlation of norketamine to acute pain relief.\[[@ref9]\]

Ketamine is a highly lipophilic compound, and it distributes rapidly from that the systemic circulation. It has been noted in humans up to that 47% of ketamine is bound to plasma proteins, and the free fraction is responsible for determining the rate of diffusion to the site of action.\[[@ref19]\] Ketamine is metabolized by in the liver by the enzymes CYP3A4, CYP2B6, CYP2C9 via N-demethylation and oxidation to norketamine (its primary active metabolite) and dehyrdoxynorketamine (a minor inactive metabolite) respectively. Norketamine is one-third to one-fifth as potent as ketamine, but it may provide prolonged anesthesia.\[[@ref20]\] It is subsequently metabolized by CYP2A6 and CYP2B6 to 4-,5-, and 6-hydroxynorketamine. After the glucuronidation of norketamines and hydroxyl norketamines in the liver, both are eliminated through the kidneys and bile.

Recent research has highlighted ketamine mediated analgesic properties and neuroprotection by its antagonism at the NMDA receptor. The amnesia and sedation produced by ketamine are associated with few cardiopulmonary adverse reactions, making it useful in procedural sedation, in particular with spontaneous ventilation commonly seen in the emergency room setting.\[[@ref21]\] The large therapeutic window and low cost of ketamine make it an attractive choice in environments where monitoring and resources are sparse.\[[@ref22]\]

Ketamine has morphine-sparing effects in subanesthetic doses, thereby increasing respiratory and hemodynamic stability. In addition, low doses of ketamine did not elicit the typical responses of increased heart rate and high blood pressure usually associated with ketamine administration.\[[@ref23]\] The combined treatment can thus reduce the side effects of opioids, and protocols have evolved for low dose ketamine administration \[Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}\]. The psychomatic effects of ketamine leading to dissociative anesthesia, emergence agitation and nausea and vomiting have led to negative comments on its clinical role.
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Low dose ketamine infusion protocol
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Orders for ketamine infusion
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Newer Uses of Ketamine {#sec1-6}
======================

The use of ketamine, a phencyclidine derivative as a potential analgesic was first identified in the early 1960s.\[[@ref2]\] It was one of the 200 derivatives investigated for clinical use. However, concerns about ketamine-induced psychotomimetic effects decreased its popularity. Initial efficacy was focused primarily on the anesthetic properties of ketamine and as an induction agent; its analgesic properties were largely ignored until it came to market in 1970, following Food and Drug Administration approval.\[[@ref2]\] Evolving research has suggested a positive role for ketamine for postoperative analgesia, applied either alone or in combination with other analgesics to adequately alleviate pain while maintaining hemodynamic stability. Ketamine is a highly lipid soluble dose-dependent anesthetic and analgesic that can be administered orally, rectally, intranasally, IV, IM, or intrathecally.\[[@ref3]\] It has been successfully applied for nociceptive and neuropathic pain.\[[@ref3]\] Although ketamine is known to increase intracranial pressure, it has been tolerated during neurosurgical procedures and patients have not sustained neurological damage following cardiopulmonary surgery.\[[@ref4]\] Nociceptive stimuli are known to trigger the release of catecholamines. This causes disturbances in respiratory and immune function. Such complications can increase hospitalization time, raise costs, and create the potential for chronic pain state.\[[@ref23]\] Ketamine offers better sedation and analgesia with fewer respiratory effects when compared to midazolam or fentanyl. In addition, it provides anxiolysis while maintaining cardiovascular stability.\[[@ref7]\] Thus, recent studies suggest its benefits in treating chronic pain,\[[@ref4]\] depression,\[[@ref24]\] as an analgesic during burn care\[[@ref2]\] and other complex and challenging subpopulations. Ketamine blocks nitric oxide, m-opioid and NMDA receptors.\[[@ref2]\] These properties support its role for chronic pain management.

Ketamine as an Analgesic {#sec1-7}
========================

Typical analgesics improve pain scores and decrease analgesic complications while allowing a quicker rehabilitation and mobilization period. Despite early reports of ketamine\'s undesired dissociative side effects, more recent research has overwhelmingly documented that the drug provides many advantages for use during surgical procedures. Addition of ketamine as an adjuvant to opioids in treating postoperative pain results in effective postoperative analgesia\[[@ref25]\] as well as attenuation of acute analgesic tolerance to opioids, and prevents rebound pain that occurs following opioid usage. Therefore, a ketamine/opioid combination can result in decreased opioid consumption and extended analgesia.\[[@ref26]\] In order to assess the efficacy of IV ketamine in minimizing postoperative analgesia, a randomized double-blind clinical trial was conducted in 40 patients undergoing elective laparoscopic cholecystectomy.\[[@ref25]\] Patients \> 18 years of age, American Society of Anesthesiologists (ASA) I and II have were included in the study. Those with body mass index of \<18 or \>35 kg/m^2^, history of chronic substance/alcohol abuse, contradiction to opioids, ketamine and nonsteroidal anti-inflammatory drugs were excluded. Two groups were identified, a propofol group (administered propofol and alfentanil with saline) and a ketamine group (administered propofol and alfentanil with ketamine). The number of additional doses of alfentanil and the total amount given intraoperatively were recorded. Assessment of pain and cumulative analgesic consumption were recorded at postanesthesia care unit (PACU) admission, PACU discharge, and postoperatively for 24 h. The study showed that patients in the ketamine group had better analgesia both intra- and post-operatively. Additionally, analgesic consumption in the ketamine group was reduced when compared to the propofol group. After this, its use as a drug for postoperative pain using patient-controlled analgesic became recognized.\[[@ref27]\]

Epidural Ketamine {#sec1-8}
=================

There has been increased interest in recent times of the use of ketamine via the epidural route for postoperative analgesia as part of a multimodal regimen. A study on 100 patients by Sethi *et al*. studied the role of ketamine via the epidural route for postoperative analgesia when combined with bupivacaine and morphine undergoing major upper abdominal surgery.\[[@ref28]\] However, there are concerns for neurotoxicity in animals\[[@ref29]\] and the report of spinal myelopathy after intrathecal injection of large doses of ketamine.\[[@ref30]\] Preservative-free ketamine in a concentration of 0.2 mg/ml was used in their study to avoid possible neurotoxicity due to epidural ketamine.

Subramaniam *et al*. studied the use of ketamine via the epidural route in 46 ASA physical status I and II patients who underwent major upper abdominal surgery.\[[@ref31]\] They found that in patients undergoing major abdominal surgery there was improved analgesia without the increase of side effects during administration of dilute epidural ketamine at a dose of 1 mg/kg with morphine 50 µg/kg. More clinical studies are warranted to evaluate the use of routine epidural ketamine administration.

Drawbacks of Ketamine {#sec1-9}
=====================

Nonmedical use of ketamine began to spread once its anesthetic and psychostimulatory properties were recognized. The use of ketamine as a "club drug" rose in popularity during the 1990s and has seen another wave of consumption in contemporary times. Ketamine is also known under the street names of "special K," "vitamin K," and "LA coke," and is used recreationally by traditionally younger generations to produce altered states of consciousness, delirium, and slowed perception of time.\[[@ref32]\] The drug is inexpensive and easily accessible and can be either ingested nasally in powder form, smoked when added to cigarettes or administered IV or SC.\[[@ref7]\] However, ketamine is also highly addicting, and multiple studies have demonstrated profound short-and long-term effects on the human body. Even occasional use of ketamine impairs working, episodic, and semantic memory.\[[@ref33]\] Magnetic resonance imaging detectable changes in the brain were studied in 21 ketamine addicts to note the various regions in the human brain that are susceptible to chronic ketamine injury. The ages of the included subjects ranged between 19 and 48 years and those with a previous history of brain tumor or neurological disease were excluded from the study. The subjects had been using ketamine in doses of 0.2-3 g/day over duration of 0.5-12 years. Atrophy was evident in frontal, parietal, occipital cortices, prefrontal lobes, brain stem and corpus striatum of addicts with the severity of lesions depending on the duration of addiction.\[[@ref34]\] This is especially concerning as users and abusers of ketamine tend to be adolescents or young adults. In this regard, ketamine can cross the placenta into fetal circulation, leading to atrophy of the fetal brain.\[[@ref10]\] Another drawback of ketamine is its damaging effects on the bladder and renal system, leading to bleeding and incontinence.\[[@ref32]\]

While ketamine alone or in combination with other drugs has proved successful in many realms, its usefulness is limited. Ketamine has been found to worsen the behaviors of individuals with obsessive-compulsive disorder, creating delayed-onset suicidal ideation.\[[@ref35]\] Individuals with Kisbourne syndrome, also known as opsoclonus-myoclonus ataxia, appear to develop increased myoclonus and opsoclonia when administered ketamine and atropine.\[[@ref36]\] Due to the potential for hallucinations, patients with psychiatric ailments or those abusing alcohol or amphetamines should not receive ketamine, as it may worsen preexisting conditions.\[[@ref3]\]

Conclusion {#sec1-10}
==========

In summary, ketamine is a strong analgesic employable in subanesthetic without major neuropsychiatric adverse effects. Ketamine decreases pain intensity in the postoperative period, and it has been shown clinically to decrease opioid consumption, decrease the side effects of opioids and increase the time for rescue analgesics-all these are attractive properties that suggest a role for ketamine as a useful adjuvant in the treatment of postoperative pain. In addition to further exploring the role of ketamine as an adjuvant for perioperative pain control, continued research is needed to determine if perioperative ketamine is useful for the treatment of pain after surgery known to result in severe pain and in the prevention and treatment of chronic pain.
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